Latest News About Devonian

Here are the latest publicly available updates on Devonian Health Group Inc. (DVHGD/DVHGF) as of now:

• Devonian Health Group has been active with new data on its lead product Thykamine, including preclinical results and strategic updates around potential expansions of its therapeutic pipeline. These developments have been covered in industry press and company disclosures in early 2026.[3][4]
• The company has announced leadership and financing activity, including executive changes and share-related corporate actions (such as share consolidation discussions ahead of potential US listing), reflecting ongoing efforts to position for growth and possible market expansion.[5][3]
• Coverage from financial news outlets and press wires during late 2025 and early 2026 highlights Devonian’s participation in industry conferences and capital-raising activity, with updates on private placements and financial governance.[4][6]

Notes

• Devonian Health Group operates in the botanical pharmaceutical space, with Thykamine as a lead product candidate and ongoing regulatory and clinical development efforts. This context underpins the recent news cycle around data updates, executive moves, and financing activities.[1][3]
• If you want, I can narrow to a specific aspect (Thykamine data results, CFO/board changes, or financing events) or pull the exact press release dates and quotes.[6][4]

Would you like a quick summary focused on a particular subtopic or a timeline of events with links?

Citations:

• Devonian Health Group news and Thykamine data coverage[3]
• CFO changes and stock option-related updates[3]
• Financing activity and press releases from 2025-2026[4][6]